CloneID: GMA1
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was developed by fusing pooled lymph node lymphocytes from cancer patients with the human lymphoblastoid cell line, SHFP-1.
Origin Pub PMID: 9627053
Buffer Composition: PBS only.
Chimeric Use Statement: This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody is specific for the tumor-associated gangliosides GD3, GD2, and GM3. It showed minimal or no activity against GD1a, GD1b, GT1b, and GQ1b.
Application Notes (Clone): The specificity of the original antibody (human IgG1) was evaluated using ELISA and TLC. It exhibited high specificity for major tumor-associated gangliosides GD3, GD2, and GM3, with minimal cross-reactivity observed with other gangliosides such as GD1b, GT1b, and GQ1b. GD3 demonstrated the highest binding affinity, while GM3 exhibited the lowest. Additionally, the antibody showed binding to melanoma (SK-MEL-28), stomach (KATO-III), pancreas (PANC-1), and neuroblastoma (U87MG) cell lines in an enzyme immunoassay (EIA). It reacted with both live and fixed SK-MEL-28 and PANC-1 cells in IF and FACS assays, indicating its ability to bind both cell surface and intracellular antigens. A recombinant version of the antibody was developed and shown to have similar reaction characteristics as the antibody produced by the hybridoma cell line, demonstrating that the specificity was not altered during molecular cloning (EP1056861A2) (Mukerjee et al., 1998; PMID: 9627053).